Francisco Llinares

Dr. Francisco Llinares

orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2006 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
MBMiguel F. Braña
Miguel F. Braña
AGAna Gradillas
Ana Gradillas
AOAngel G. Ovalles
Angel G. Ovalles
BLBerta López
Berta López
N. AceroN. Acero
N. Acero
DMDolores Muñoz Mingarro
Dolores Muñoz Mingarro

8 October 2005 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
MBMiguel F. Braña
Miguel F. Braña
MCMónica Cacho
Mónica Cacho
MGM. Luisa García
M. Luisa García
Elena Pérez-MayoralElena Pérez-Mayoral
Elena Pérez-Mayoral
BLBerta López
Berta López
LMLaurent Meijer
Laurent Meijer

22 November 2002 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
MBMiguel F. Braña
Miguel F. Braña
MCMónica Cacho
Mónica Cacho
MGMario A. García
Mario A. García
Beatriz de Pascual-TeresaBeatriz de Pascual-Teresa
Beatriz de Pascual-Teresa
ARAna Ramos
Ana Ramos
MYMercedes Yuste
Mercedes Yuste

1 August 2003 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
DMD Muñoz-Mingarro
D Muñoz-Mingarro
N. AceroN. Acero
N. Acero
FLFrancisco Llinares
Francisco Llinares
JPJ.M Pozuelo
J.M Pozuelo
Antonio Galán de MeraAntonio Galán de Mera
Antonio Galán de Mera
CPC Pérez
C Pérez

20 March 2004 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
MBMiguel F. Braña
Miguel F. Braña
AGAna Gradillas
Ana Gradillas
AGAngel Gómez
Angel Gómez
N. AceroN. Acero
N. Acero
FLFrancisco Llinares
Francisco Llinares
AEAntonio Espinosa
Antonio Espinosa

1 June 2019 in FEMS Microbiology Letters
Verified
Journal Article
Closed access
SRSergio Rius-Rocabert
Sergio Rius-Rocabert
FLFrancisco Llinares
Francisco Llinares
MPMaria Jose Pozuelo
Maria Jose Pozuelo
AGAntonia García
Antonia García
ENEstanislao Nistal-Villan
Estanislao Nistal-Villan
More than a century ago, independent groups raised the possibility of using bacteria to selectively infect tumours. Such treatment induces an immune reaction that can cause tumour rejection and protect the patient against further recurrences. One of the first holistic approximations to use bacteria in cancer treatment was performed by William Coley, considered the father of immune-therapy, at the end of XIX century. Since then, many groups have used different bacteria to test their antitumour activity in animal models and patients. The basis for this reactivity implies that innate immune responses activated upon bacteria recognition, also react against the tumour. Different publications have addressed several aspects of oncolytic bacteria. In the present review, we will focus on revisiting the historical aspects using bacteria as oncolytic agents and how they led to the current clinical trials. In addition, we address the molecules present in oncolytic bacteria that induce specific toxic effects against the tumors as well as the activation of host immune responses in order to trigger antitumour immunity. Finally, we discuss future perspectives that could be considered in the different fields implicated in the implementation of this kind of therapy in order to improve the current use of bacteria as oncolytic agents.